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BACKGROUND
The roles of anticoagulation alone or with an antiplatelet agent after transcatheter 
aortic-valve implantation (TAVI) have not been well studied.
METHODS
We performed a randomized trial of clopidogrel in patients undergoing TAVI who 
were receiving oral anticoagulation for appropriate indications. Patients were as-
signed before TAVI in a 1:1 ratio not to receive clopidogrel or to receive clopidogrel 
for 3 months. The two primary outcomes were all bleeding and non–procedure-
related bleeding over a period of 12 months. Procedure-related bleeding was de-
fined as Bleeding Academic Research Consortium type 4 severe bleeding, and there-
fore most bleeding at the puncture site was counted as non–procedure-related. The 
two secondary outcomes were a composite of death from cardiovascular causes, 
non–procedure-related bleeding, stroke, or myocardial infarction at 12 months 
(secondary composite 1) and a composite of death from cardiovascular causes, 
ischemic stroke, or myocardial infarction (secondary composite 2), both tested for 
noninferiority (noninferiority margin, 7.5 percentage points) and superiority.
RESULTS
Bleeding occurred in 34 of the 157 patients (21.7%) receiving oral anticoagulation 
alone and in 54 of the 156 (34.6%) receiving oral anticoagulation plus clopidogrel 
(risk ratio, 0.63; 95% confidence interval [CI], 0.43 to 0.90; P = 0.01); most bleeding 
events were at the TAVI access site. Non–procedure-related bleeding occurred in 
34 patients (21.7%) and in 53 (34.0%), respectively (risk ratio, 0.64; 95% CI, 0.44 to 
0.92; P = 0.02). Most bleeding occurred in the first month and was minor. A second-
ary composite 1 event occurred in 49 patients (31.2%) receiving oral anticoagulation 
alone and in 71 (45.5%) receiving oral anticoagulation plus clopidogrel (difference, 
−14.3 percentage points; 95% CI for noninferiority, −25.0 to −3.6; risk ratio, 0.69; 95% 
CI for superiority, 0.51 to 0.92). A secondary composite 2 event occurred in 21 patients 
(13.4%) and in 27 (17.3%), respectively (difference, −3.9 percentage points; 95% CI for 
noninferiority, −11.9 to 4.0; risk ratio, 0.77; 95% CI for superiority, 0.46 to 1.31).
CONCLUSIONS
In patients undergoing TAVI who were receiving oral anticoagulation, the inci-
dence of serious bleeding over a period of 1 month or 1 year was lower with oral 
anticoagulation alone than with oral anticoagulation plus clopidogrel. (Funded by 
the Netherlands Organization for Health Research and Development; POPular 
TAVI EU Clinical Trials Register number, 2013 - 003125 - 28; ClinicalTrials.gov num-
ber, NCT02247128.)
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Anticoagulation after TAVI
Transcatheter aortic-valve implan-tation (TAVI) is used in patients with symptomatic severe aortic stenosis.1-8 The 
procedure is complicated by major and life-threat-
ening bleeding in 3 to 13% of patients, and strokes 
occur in 1 to 12% at 1 year after TAVI.7-16 Atrial 
fibrillation is common in patients undergoing 
TAVI and constitutes an indication for long-term 
oral anticoagulation therapy with a vitamin K 
antagonist or direct-acting oral anticoagulant.17,18 
Current practice guidelines on antithrombotic 
treatment in patients who have an indication for 
anticoagulation after TAVI are based on expert 
opinion and suggest a vitamin K antagonist either 
alone19 or in combination with aspirin or clopi-
dogrel.20 The rationale for additional antiplatelet 
therapy after TAVI is to reduce the risk of throm-
boembolic complications, but the trade-off of the 
risk of bleeding has not been well studied.14,21
The current trial (POPular TAVI) of antithrom-
botic therapy after TAVI involves two cohorts. 
This report describes the results in cohort B, 
which included patients who had an established 
indication for long-term oral anticoagulation. 
Our investigation of cohort A, which includes 
patients who did not have an indication for long-
term anticoagulation, has not been completed.
Me thods
Trial Design and Oversight
The POPular TAVI trial is an investigator-initiat-
ed, parallel-group, randomized, open-label trial 
performed at 17 European sites (9 in the Neth-
erlands, 6 in Belgium, 1 in the Czech Republic, 
and 1 in Luxembourg). Details of the design 
have been described previously,22 and the trial 
protocol is available with the full text of this 
article at NEJM.org. The trial is sponsored by the 
Netherlands Organization for Health Research 
and Development, which has had no role in the 
design or execution of the trial or in the analysis 
of the data. There is no industry involvement in 
the trial.
The trial protocol was approved by the na-
tional authorities and ethics committees in each 
country and by institutional research boards at 
each participating site. An independent data and 
safety monitoring board provided oversight by 
periodically reviewing all reported outcomes. Ad-
judication of all reported outcomes was executed 
by an independent clinical-event committee, whose 
members were unaware of the trial-group assign-
ments. Trial monitoring was performed by an 
independent and external clinical research orga-
nization (Research Drive, Norg, the Netherlands).
The first two authors and the last author pre-
pared all drafts of the manuscript. All the au-
thors reviewed the manuscript and attest to the 
accuracy and completeness of the data, the fidel-
ity of the trial to the protocol, and the accurate 
reporting of adverse events.
Patients
All patients suitable for TAVI, as determined by 
a dedicated heart team at each institution con-
sisting of at least one interventional cardiologist 
and one cardiothoracic surgeon, were eligible for 
enrollment in the trial. Before randomization, 
patients were divided into two cohorts: those who 
had no indication for long-term oral anticoagu-
lation (cohort A), and those, whose data are re-
ported here, who had an established indication 
for long-term oral anticoagulation (cohort B). The 
main exclusion criteria were drug-eluting stent 
implantation within 3 months or bare-metal stent 
implantation within 1 month before the TAVI pro-
cedure and allergy to or unacceptable side effects 
from clopidogrel. Details regarding inclusion and 
exclusion criteria are provided in Table S1 in the 
Supplementary Appendix, available at NEJM.org. 
Before the TAVI procedure was performed, all the 
patients provided written informed consent to 
participate in the trial.
Randomization and Trial Procedures
All the patients were receiving oral anticoagulation 
before randomization. Patients continued oral an-
ticoagulation, which could be with a vitamin K 
antagonist or with a direct-acting oral antico-
agulant, depending on the drug that the patient 
was using before randomization. Patients were 
randomly assigned before TAVI, in a 1:1 ratio, to 
receive either clopidogrel or no clopidogrel for 
3 months. Randomization was executed by an 
electronic Web-response randomization system, 
with stratification according to center.
The TAVI procedures were performed accord-
ing to the local protocol at each participating site. 
The trial protocol advised physicians to continue 
oral anticoagulation during admission for the 
TAVI procedure with a goal of an international 
normalized ratio of 2.0 for vitamin K antago-
nists, but the choice to either continue or inter-
rupt oral anticoagulation periprocedurally was 
left to the discretion of the attending physician. 
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During the procedure, the use of unfractionated 
heparin was recommended with the goal of an 
activated clotting time of more than 250 seconds, 
or more than 200 seconds in patients with con-
tinuation of oral anticoagulation therapy. In pa-
tients assigned to oral anticoagulation plus 
clopidogrel, an initial loading dose of 300 mg of 
clopidogrel was administered either 1 day before 
or on the day of TAVI, followed by 75 mg once a 
day for 3 months, with discretionary allowance 
of cessation of clopidogrel 1 month earlier or 
later than 3 months.
Follow-up visits for routine care were sched-
uled at 30 days, 6 months, and 12 months, 
which could be performed in either the treating 
or referring hospital. Transthoracic echocardiog-
raphy was performed 6 months after TAVI. All 
the patients were asked to complete a question-
naire at 3, 6, and 12 months after TAVI regard-
ing the occurrence of primary and secondary out-
comes, the prescribed medication, health status, 
and quality of life. Follow-up data were collected 
and adjudicated centrally by the research depart-
ment of the coordinating center and assessed by 
persons unaware of the trial-group assignments. 
Data were obtained from hospital electronic pa-
tient records and the questionnaires and, if 
necessary, the patient, the patient’s primary care 
physician (i.e., when death occurred at home), or 
the patient’s pharmacist.
Outcomes
All the patients were followed for at least 1 year 
after TAVI. The two primary outcomes were all 
bleeding and non–procedure-related bleeding. 
Bleeding events and vascular complications were 
classified according to the Valve Academic Re-
search Consortium-2 (VARC-2) definitions (Table 
S2).23 Because the VARC-2 classification does not 
distinguish between procedure-related and non–
procedure-related bleeding events, procedure-
related events were defined as Bleeding Academic 
Research Consortium (BARC) type 4 severe bleed-
ing.24 This category is defined by any of the 
following: perioperative intracranial bleeding 
within 48 hours, reoperation after closure of 
sternotomy for the purpose of controlling bleed-
ing, transfusion of 5 or more units of whole blood 
or packed red cells within a 48-hour period, or 
chest-tube output of 2 or more liters within a 
24-hour period. Non–procedure-related bleeding 
consisted of all VARC-2 bleeding, excluding BARC 
type 4 severe bleeding; therefore, most bleeding 
at the puncture site was counted as non–proce-
dure-related. Minor procedure-related bleeding 
events, not classified as BARC type 4, were counted 
separately and included in the non–procedure-
related bleeding outcome. Bleeding events were 
also classified with the use of BARC, Thromboly-
sis in Myocardial Infarction (TIMI), and Global 
Utilization of Streptokinase and Tissue Plasmino-
gen Activator for Occluded Arteries (GUSTO) 
definitions (Table S2). Definitions of these out-
comes are provided in the Supplementary Ap-
pendix.
There were two secondary outcomes: one was 
a composite of death from cardiovascular causes, 
non–procedure-related bleeding, stroke from any 
cause, or myocardial infarction (secondary com-
posite 1); the other was a composite of death from 
cardiovascular causes, ischemic stroke, or myo-
cardial infarction (excluding bleeding) (second-
ary composite 2). We used these two composite 
outcomes to infer net clinical benefit and effi-
cacy, respectively. The plan was to test noninfe-
riority for secondary outcomes and, if this was 
shown, to test superiority.
Statistical Analysis
The hypothesis was that oral anticoagulation 
alone would be superior to oral anticoagulation 
plus 3 months of clopidogrel with respect to the 
incidence of bleeding (the primary outcome), 
while being noninferior with respect to the sec-
ondary outcomes. The primary and secondary 
outcomes were powered separately. The primary 
outcome was powered both for all bleeding and 
non–procedure-related bleeding. We estimated 
the incidence of all bleeding to be 18% among 
patients receiving oral anticoagulation alone and 
36% among those receiving oral anticoagulation 
plus clopidogrel. We estimated the incidence of 
non–procedure-related bleeding to be 13% and 
26%, respectively. These estimates were based 
on limited published data.25,26 Accordingly, we 
calculated that 284 patients would be needed for 
the trial to show superiority with 80% power 
and a two-sided alpha of 0.05 for the primary 
outcomes.
For secondary composite 1, we estimated the 
incidence to be 31% among patients receiving 
oral anticoagulation alone and 39% among those 
receiving oral anticoagulation plus clopidogrel. 
Accordingly, we calculated that 296 patients 
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would be needed for the trial to show noninferi-
ority with a noninferiority margin of 7.5 percent-
age points for the absolute difference with 80% 
power and a one-sided alpha of 0.025. If the re-
quirement for noninferiority was met, secondary 
outcomes were tested for superiority. With ac-
counting for withdrawals and loss to follow-up, 
the sample size was set at 316. Because there 
was no plan for adjustment for multiple com-
parisons of secondary outcomes, point estimates 
and unadjusted 95% confidence intervals are 
reported, and no clinical inferences can be made 
from these results.
The main analyses were performed in the 
modified intention-to-treat population, which in-
cluded all the patients who underwent random-
ization and TAVI. Secondary analyses of the pri-
mary and secondary outcomes were performed in 
the per-protocol population.
For time-to-event analyses of the primary and 
secondary outcomes, hazard ratios and 95% 
confidence intervals were planned to be gener-
ated with Cox proportional-hazards models and 
tested by the log-rank test. Kaplan–Meier curves 
were used to show the incidence of outcomes 
over time. However, for both the primary and 
secondary outcomes, the underlying assumption 
of proportional hazards from randomization 
through 1 year was not met. We therefore per-
formed a post hoc risk-ratio analysis for 12 
months and a Cox proportional-hazards model 
for the first month. A two-sided P value of 0.05 
or less was considered to indicate statistical sig-
nificance. Analyses for the prespecified subgroups 
were performed for the primary and secondary 
outcomes with time to first event with the use of 
the Cox proportional-hazards model to evaluate 
treatment-by-subgroup interactions, but the trial 
was not powered to allow conclusions drawn from 
these subgroups. Data for patients who were lost 
to follow-up were planned to be treated as cen-
sored at the time of their last known vital status. 
Statistical analyses were performed with the use 
of R software, version 3.6.1 (R Foundation for 
Statistical Computing).
R esult s
Trial Population
From December 2013 through August 2018, a 
total of 326 patients who were receiving oral 
anticoagulation were randomly assigned in a 1:1 
ratio to receive either clopidogrel or no clopido-
grel for 3 months (Fig. 1). After randomization, 
13 patients were excluded from analysis for the 
following reasons: TAVI was not initiated, was 
aborted, or was converted to an open procedure 
(5 patients); patients withdrew consent (5); or 
patients did not meet inclusion criteria (3). There-
fore, 157 patients receiving oral anticoagulation 
alone and 156 receiving oral anticoagulation 
plus clopidogrel were included in the modified 
intention-to-treat primary analyses.
Baseline characteristics were similar in the 
two groups (Table 1). The mean (±SD) age of the 
patients was 81.0±5.9 years, and 45.4% of the 
patients were women. Procedural characteristics 
(including vascular complications), patient char-
acteristics at discharge, and echocardiographic 
findings at discharge and during follow-up are 
shown in Tables S3 through S5. No patients were 
lost to follow-up at 12 months; data on primary 
and secondary outcomes were complete for 100% 
of the patients. Among patients receiving oral 
anticoagulation plus clopidogrel, adherence to 
clopidogrel was 95.5% for the recommended 
period of 3 months. Oral anticoagulation was 
discontinued by 2 patients receiving oral antico-
agulation alone and by none receiving oral anti-
coagulation plus clopidogrel.
Primary Outcomes
At 12 months, bleeding of any type had occurred 
in 34 patients (21.7%) receiving oral anticoagu-
lation alone and in 54 patients (34.6%) receiving 
oral anticoagulation plus clopidogrel (risk ratio, 
0.63; 95% confidence interval [CI], 0.43 to 0.90; 
P = 0.01), and non–procedure-related bleeding had 
occurred in 34 patients (21.7%) and in 53 patients 
(34.0%), respectively (risk ratio, 0.64; 95% CI, 
0.44 to 0.92; P = 0.02) (Table 2, Fig. 2, and Fig. 
S2). The TAVI access site was the most common 
location of bleeding in both groups (15 of 34 
patients [44%] receiving oral anticoagulation 
alone and 27 of 54 patients [50%] receiving oral 
anticoagulation plus clopidogrel) and was classi-
fied as non–procedure-related because it was not 
BARC type 4 (Tables S6 and S7). Severe proce-
dure-related bleeding, defined as BARC type 4, 
was observed in 1 patient receiving oral antico-
agulation plus clopidogrel and in none receiving 
oral anticoagulation alone, and this single event 
was the difference between the two primary out-
comes.
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Post hoc Cox proportional-hazards analysis 
of the primary outcomes during the first month, 
the period during which most bleeding occurred, 
is shown in Table S10, with hazard ratios of 0.60 
(95% CI, 0.38 to 0.97) for all bleeding and 0.62 
(95% CI, 0.39 to 1.00) for non–procedure-related 
bleeding. Sensitivity analyses of the primary out-
comes and the secondary outcomes are shown in 
Tables S8 and S9, respectively, and are in the 
same direction as the primary analysis. Prespeci-
fied subgroup analyses of the primary outcomes 
are shown in Figures S3 and S4.
Secondary Outcomes
A secondary composite 1 event (death from car-
diovascular causes, non–procedure-related bleed-
ing, stroke from any cause, or myocardial infarc-
tion) occurred in 49 patients (31.2%) receiving 
oral anticoagulation alone and in 71 patients 
(45.5%) receiving oral anticoagulation plus clopido-
grel (difference, −14.3 percentage points; 95% CI 
for noninferiority, −25.0 to −3.6; risk ratio, 0.69; 
95% CI for superiority, 0.51 to 0.92) (Table 2 and 
Fig. 3A). A secondary composite 2 event (death 
from cardiovascular causes, ischemic stroke, or 
myocardial infarction) occurred in 21 patients 
(13.4%) receiving oral anticoagulation alone and 
in 27 patients (17.3%) receiving oral anticoagula-
tion plus clopidogrel (difference, −3.9 percentage 
points; 95% CI for noninferiority, −11.9 to 4.0; 
risk ratio, 0.77; 95% CI for superiority, 0.46 to 
1.31) (Table 2 and Fig. 3B). These results showed 
that no receipt of clopidogrel was noninferior to 
receipt of clopidogrel for both secondary out-
comes by the prespecified margin of 7.5 percent-
age points, superior for the secondary outcome 
that included bleeding (secondary composite 1), 
and not superior for the secondary outcome that 
excluded bleeding (secondary composite 2). No 
clinical inferences can be drawn for these sec-
Figure 1. Randomization and Follow-up.
TAVI denotes transcatheter aortic-valve implantation.
326 Patients underwent randomization
164 Were assigned to receive oral
anticoagulation monotherapy
162 Were assigned to receive oral anti-
coagulation plus clopidogrel for 3 mo
6 Were excluded
1 Withdrew written informed
consent
3 Had no initiation of TAVI
or had procedure that was
aborted or converted
to open surgery
2 Had screening failure
7 Were excluded
4 Withdrew written informed
consent
2 Had no initiation of TAVI
or had procedure that was
aborted or converted
to open surgery
1 Had screening failure
157 Were included in the intention-
to-treat population
156 Were included in the intention-
to-treat population
157 Were eligible for analysis 156 Were eligible for analysis
157 Completed 12-mo follow-up 156 Completed 12-mo follow-up
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Table 1. Baseline Characteristics of the Patients.*
Characteristic
Oral Anticoagulation 
(N = 157)
Oral Anticoagulation 
plus Clopidogrel 
(N = 156)
Age — yr 80.9±6.2 81.0±5.5
Female sex — no. (%) 69 (43.9) 73 (46.8)
NYHA class III or IV — no. (%) 119 (75.8) 110 (70.5)
Body-mass index† 27.4±5.3 27.5±5.1
Logistic EuroSCORE — %‡
Median 15.6 14.1
IQR 9.2–23.8 10.6–22.8
Society of Thoracic Surgeons risk score — %§
Median 3.2 3.1
IQR 2.2–4.8 2.3–4.5
Indication for TAVI — no. (%)
Normal-flow, high-gradient aortic stenosis 98 (62.4) 98 (62.8)
Low-flow, low-gradient aortic stenosis 51 (32.5) 50 (32.1)
Pure aortic regurgitation 6 (3.8) 4 (2.6)
Combination of above 2 (1.3) 4 (2.6)
Atrial fibrillation — no. (%)¶ 150 (95.5) 147 (94.2)
Hypertension — no. (%) 115 (73.2) 105 (67.3)
Diabetes mellitus — no. (%) 43 (27.4) 46 (29.5)
Coronary artery disease — no. (%) 65 (41.4) 69 (44.2)
Previous myocardial infarction — no. (%) 14 (8.9) 20 (12.8)
Peripheral artery disease — no. (%) 30 (19.1) 28 (17.9)
Previous stroke — no. (%) 15 (9.6) 15 (9.6)
Estimated glomerular filtration rate — ml/min/1.73 m2‖ 53.4±17.7 55.6±17.1
Chronic obstructive pulmonary disease — no. (%) 33 (21.0) 30 (19.2)
Previous coronary-artery bypass grafting — no. (%) 30 (19.1) 30 (19.2)
Previous aortic-valve surgery — no. (%) 7 (4.5) 9 (5.8)
Left ventricular ejection fraction — no. (%)
>50% 91 (58.0) 97 (62.2)
31–50% 54 (34.4) 46 (29.5)
≤30% 12 (7.6) 13 (8.3)
*  Plus–minus values are means ±SD. There were no significant differences between the two groups. Percentages may not 
total 100 because of rounding. IQR denotes interquartile range, NYHA New York Heart Association, and TAVI trans-
catheter aortic-valve implantation.
†  The body-mass index is the weight in kilograms divided by the square of the height in meters.
‡  Values for the logistic-regression version of European System for Cardiac Operative Risk Evaluation (EuroSCORE) 
range from 0 to 100%, with higher values indicating a higher risk of death after cardiac surgery.
§  Society of Thoracic Surgeons risk scores range from 0 to 100%, with higher scores indicating a higher risk of death af-
ter cardiac surgery.
¶  Shown are patients with a history of atrial fibrillation and those with atrial fibrillation newly diagnosed on admission. 
Other indications for oral anticoagulation therapy included lung embolism, deep-vein thrombosis, poor left ventricular 
ejection fraction (including left ventricle aneurysms), and extensive arterial vascular disease.
‖  In the calculation of the estimated glomerular filtration rate, the creatinine clearance was calculated with the use of the 
Chronic Kidney Disease Epidemiology Collaboration formula.
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ondary outcome results because of the lack of a 
plan for correction for multiple comparisons.
In post hoc analyses, the individual compo-
nents of the secondary outcomes were similar in 
the two groups (Table 2). Secondary outcomes 
across prespecified subgroups are shown in Fig-
ures S5 and S6. Post hoc Cox proportional-haz-
ards analysis over a period of 3 months for the 
secondary outcomes is shown in Table S11.
Stroke occurred in nine patients (5.7%) re-
ceiving oral anticoagulation alone and in nine 
patients (5.8%) receiving oral anticoagulation plus 
clopidogrel. There was one hemorrhagic stroke 
(intraparenchymal) in a patient receiving oral anti-
coagulation alone and none in those receiving oral 
anticoagulation plus clopidogrel. Fatal stroke was 
observed in one patient receiving oral anticoagu-
lation alone and in two patients receiving oral 
anticoagulation plus clopidogrel.
Discussion
In this cohort of the POPular TAVI trial, we inves-
tigated antithrombotic treatment with oral anti-
coagulation alone as compared with oral antico-
agulation plus clopidogrel for 3 months after 
Table 2. Primary and Secondary Outcomes.*
Outcome
Oral Anticoagulation 
(N = 157)
Oral Anticoagulation 
plus Clopidogrel 
(N = 156)
Risk Ratio 
(95% CI)
Absolute Difference 
(95% CI)
P 
Value
number (percent) percentage points
Primary outcomes
All bleeding 34 (21.7) 54 (34.6) 0.63 (0.43 to 0.90) 0.01
Non–procedure-related bleeding 34 (21.7) 53 (34.0) 0.64 (0.44 to 0.92) 0.02
Secondary outcomes
Secondary composite 1†
Noninferiority analysis 49 (31.2) 71 (45.5) −14.3 (−25.0 to −3.6)
Superiority analysis 49 (31.2) 71 (45.5) 0.69 (0.51 to 0.92)
Secondary composite 2‡
Noninferiority analysis 21 (13.4) 27 (17.3) −3.9 (−11.9 to 4.0)
Superiority analysis 21 (13.4) 27 (17.3) 0.77 (0.46 to 1.31)
Death from any cause 21 (13.4) 24 (15.4) 0.87 (0.51 to 1.50)
Death from cardiovascular causes 13 (8.3) 20 (12.8) 0.65 (0.33 to 1.25)
Stroke 9 (5.7) 9 (5.8) 0.99 (0.41 to 2.44)
Ischemic 8 (5.1) 9 (5.8) 0.88 (0.35 to 2.23)
Hemorrhagic 1 (0.6) 0
Myocardial infarction 1 (0.6) 1 (0.6) 0.99 (0.06 to 15.75)
VARC-2 bleeding
Life-threatening or disabling bleeding 6 (3.8) 13 (8.3) 0.46 (0.18 to 1.18)
Major bleeding 8 (5.1) 13 (8.3) 0.61 (0.26 to 1.43)
Major, life-threatening, or disabling 
bleeding
14 (8.9) 26 (16.7) 0.54 (0.29 to 0.99)
Minor bleeding 20 (12.7) 28 (17.9) 0.71 (0.42 to 1.21)
*  All outcomes were confirmed by an independent adjudication committee. The 95% confidence intervals for the secondary outcomes were 
not adjusted for multiple comparisons, and no clinical inferences can be made from these analyses. Individual elements of the primary and 
secondary outcomes were analyzed post hoc, and the 95% confidence intervals were not adjusted for multiple comparisons. VARC-2 de-
notes Valve Academic Research Consortium-2.
†  A secondary composite 1 event was death from cardiovascular causes, non–procedure-related bleeding, stroke from any cause, or myocar-
dial infarction.
‡  A secondary composite 2 event was death from cardiovascular causes, ischemic stroke, or myocardial infarction.
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TAVI, in patients who were receiving indicated 
long-term oral anticoagulation. Antithrombotic 
treatment with oral anticoagulation alone was as-
sociated with a lower incidence of serious bleed-
ing events than oral anticoagulation plus clopi-
dogrel with regard to the primary outcomes of 
all bleeding and of non–procedure-related bleed-
ing at 12 months. Our definition of procedural 
bleeding was BARC type 4, indicating severe 
bleeding and excluding most bleeding at the 
puncture site. The planned 1-year analysis showed 
nonproportional hazards, but post hoc risk ra-
tios with respect to all bleeding and non–proce-
dure-related bleeding also favored monotherapy 
at 1 month and at 1 year. Most bleeding occurred 
in the first few weeks after the procedure, as 
shown by post hoc landmark analysis at 1 month 
and is evident from visual inspection of the Kap-
lan–Meier curves. Minor bleeding rather than 
major bleeding, as defined by several classifica-
tions, contributed to this difference. The differ-
ence in bleeding events occurred mainly in the 
first month after TAVI, during which clopidogrel 
was administered, resulting in nonproportional 
hazards and requiring analysis by risk ratios.
As for the secondary outcomes, between-
group differences that were not adjusted for 
multiple comparisons were in the same direc-
tions as the primary outcomes for noninferiority 
with regard to secondary composite 1 and sec-
ondary composite 2. The former, but not the 
latter, secondary outcome was in the same direc-
tion as the primary outcomes for superiority. 
The lack of a plan for multiple comparisons of 
secondary outcomes did not allow clinical infer-
ences from these secondary outcome data.
Current guidelines recommend the use of a 
vitamin K antagonist with or without antiplate-
let therapy for 3 to 6 months after TAVI in pa-
tients with a long-term indication for oral anti-
coagulation.19,20 The rationale for additional 
antiplatelet therapy is to prevent thromboem-
Figure 2. Primary Outcome of All Bleeding.
Shown are time-to-event Kaplan–Meier curves of the primary outcome of all bleeding. The inset shows the same 
data on an enlarged y axis. Given the nonproportionality of the hazards during the follow-up period, a post hoc risk-
ratio analysis with 95% confidence intervals was performed. Results of a post hoc Cox proportional-hazards analy-
sis over a period of 1 month for the primary outcome are shown in Table S10.
C
um
ul
at
iv
e 
Pe
rc
en
ta
ge
 o
f P
at
ie
nt
s 
w
ith
 B
le
ed
in
g
100
75
50
25
0
0 45 90 135 225180 315270 360
40
30
20
10
0
0 45 90 135 225180 315270 360
Days since TAVI Procedure
Risk ratio for oral anticoagulant vs.
oral anticoagulant+clopidogrel,
0.63 (95% CI, 0.43–0.90)
No. at Risk
Oral anticoagulant+clopidogrel
Oral anticoagulant
156
157
108
126
98
123
96
123
91
117
92
123
88
112
91
114
87
110
Oral anticoagulant+clopidogrel
Oral anticoagulant
+
+
++
+ +
+
+
+ +
+ + + +
+
+
+
+
+
+ + + + +
+
+ +
+
+
+
+ +
+ +
+
+
+ +
+ + + +
++
+
+
+
+
+ + + + +
+
+ +
++
The New England Journal of Medicine 
Downloaded from nejm.org at ERASMUS UNIVERSITY on May 12, 2020. For personal use only. No other uses without permission. 
 Copyright © 2020 Massachusetts Medical Society. All rights reserved. 
n engl j med 382;18 nejm.org April 30, 20201704
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
A Death from Cardiovascular Causes, Non–Procedure-Related Bleeding, Stroke, or MI (Secondary Composite 1)
B Death from Cardiovascular Causes, Ischemic Stroke, or MI (Secondary Composite 2)
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bolic complications before endothelialization of 
the valve is completed.14,21 However, observa-
tional data from patients with atrial fibrillation 
undergoing TAVI have shown a higher incidence 
of bleeding with a vitamin K antagonist plus a 
single antiplatelet therapy than with vitamin K 
antagonist monotherapy, with a similar inci-
dence of thromboembolic events in the two 
groups.14,15,21
Reported incidences of stroke among patients 
with atrial fibrillation range from 3 to 12% in 
the first year after TAVI, of which approximately 
one fourth occurred within the first 24 hours 
and half within 30 days after TAVI.14-16 Whereas 
periprocedural stroke is considered to be caused 
by embolization of calcified native valve or aor-
tic tissue, stroke at later times is more often 
related to valve thrombosis (i.e., native or pros-
thetic valve thrombosis or atherothrombotic 
disease) and is therefore more amenable to anti-
thrombotic therapy.27 The incidences of all types 
of stroke and of ischemic stroke in cohort B of 
the POPular TAVI trial were similar in the trial 
groups at 12 months and were similar to pub-
lished observational data.14-16 There was one 
hemorrhagic stroke in a patient receiving oral 
anticoagulation alone. Fatal stroke occurred in 
one patient receiving oral anticoagulation alone 
and in two patients receiving oral anticoagulation 
plus clopidogrel.
The current trial included patients receiving 
either a vitamin K antagonist or a direct-acting 
oral anticoagulant. Prespecified subgroup analy-
ses showed a possible benefit of direct-acting oral 
anticoagulants over vitamin K antagonists with 
regard to the primary outcomes (Figs. S3 and S4); 
however, no conclusions can be drawn from 
these analyses because this trial was neither 
designed nor powered to assess differences be-
tween subgroups. A trial involving patients with-
out an established indication for oral anticoagu-
lation after undergoing TAVI showed that 
rivaroxaban (10 mg daily) with aspirin was as-
sociated with a higher risk of bleeding and a 
higher risk of death or thromboembolic compli-
cations than was aspirin with clopidogrel.28
Our trial has several limitations. First, the 
trial was an open-label trial and thereby poten-
tially subject to reporting and ascertainment 
biases. However, trial outcomes were prespeci-
fied according to standardized definitions and 
were adjudicated by a clinical-events committee 
whose members were unaware of the trial-group 
assignments. Second, the trial was powered to 
detect a difference in bleeding and secondary 
composite 1. However, the underlying assump-
tion of proportionality for hazards for 12 months 
was not met, and an alternative plan was not 
prespecified in the statistical analysis plan. We 
therefore calculated post hoc risk ratios, and 
these were in the same direction as the primary 
analysis. Third, comparisons between trial 
groups for the secondary outcomes were not 
adjusted for multiple comparisons, and no clini-
cal inferences can be made from these results. 
Fourth, the results of this report do not apply to 
patients undergoing TAVI who do not have an 
indication for long-term oral anticoagulation. 
This population is currently under investigation 
in cohort A of the POPular TAVI trial. Fifth, the 
most important limitation is the unconventional 
definition of procedural bleeding as BARC type 
4, which represents severe bleeding and would 
exclude most bleeding at the puncture site.
Among patients with long-term indications 
for oral anticoagulation undergoing TAVI, oral 
anticoagulation alone was associated with a 
lower incidence of serious bleeding over a period 
of either 1 month or 1 year than was anticoagula-
tion plus clopidogrel. Composite outcomes with 
and without bleeding were in the same direction 
as the primary outcomes for noninferiority; supe-
riority of oral anticoagulation alone was shown 
for the composite outcome that included bleeding 
but not for the outcome that excluded bleeding.
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